Leveraging the information from our in vivo pharmacokinetic analysis of STO-609, we demonstrate that pharmacological inhibition of CaMKK2 reverses the hallmarks of hepatic steatosis in two mouse models of NAFLD. The gene discussed is CAMKK2; the disease is metabolic dysfunction-associated steatotic liver disease.